B lymphocytes exhibit dual roles in tumorigenesis, acting as both allies and adversaries in the tumor microenvironment (TME).

In a series of experiments in mice and human tissues, the researchers showed that different tumors release varying amounts of the chemokine CXCL13. Breast cancers and melanomas release relatively ...

Breast cancers and melanomas release relatively small quantities of CXCL13. However, if these tumor cells spread to the lung, they can trigger clot formation by releasing CXCL13 and locally ...

The secondary endpoint of mPFS was 7.7 months across all patients. The exploratory biomarker of CXCL13, a B-cell chemokine and lymphoid structure marker associated with clinical activity ...

Here, we designed a general strategy to improve the magnitude and breadth of the antibody response induced by circRNA vaccines and remodeled the immune microenvironment of lymph nodes by integrating ...

Vaccinex has developed anti-CXCL13 monoclonal antibodies to treat autoimmune diseases, inflammatory diseases, and cancers. The patent covers a method for treating diseases by administering antibodies ...

A newly defined threshold for the concentration of the cytokine CXCL13 may improve the diagnosis of neuroborreliosis. The clinical diagnosis of this disease, which is caused by infections from ...

CXCL13, a signaling protein that is produced immediately after infection with B. burgdorferi and triggers an immune response, could provide a more accurate diagnosis—if it were known at what ...

They work together: T cells make a protein called CXCL13 that calls B cells to places of inflammation. In a disease like cancer, more CXCL is good because it brings B cells to the scene of ...